Modernization of “manufacturing technologies and controls through further advanced automation and artificial intelligence” are helping trigger Biogen’s commitment of $2 billion into its North Carolina facilities.
The Fortune 500 company based in Cambridge, Mass., opened its first campus in the Research Triangle Park in 1995. Celebrating the 30 years, the company on Monday said its two campuses will further expand “the antisense oligonucleotide capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities.”
Biogen, traded on the Nasdaq Global Select Market, had 2024 revenue of $9.68 billion, net income of $1.63 billion, and a profit margin of 17%, according to its financials.
The company’s largest manufacturing footprint is in North Carolina, with more than 1,500 employees and 400 skilled contractors in Wake and Durham counties. By volume of size, the company is the state’s largest biotechnology employer and top five of biopharmaceutical employers.
Manufacturing and quality control testing for 90% of its innovator commercial medicines happens in America.
